Hainan Boao Lecheng Administrative Bureau Visits Deep Harbour Cell Valley to Deepen Cooperation in Cell Therapy

Recently, Gao Huimin, Deputy Director of the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administrative Bureau (hereinafter referred to as the “Lecheng Administrative Bureau”), and Zhou Lianghui, General Manager of Hainan Boao Lecheng Development Holding Co., Ltd., led a delegation to visit Deep Harbour Cell Valley. Themed “Deepening Cooperation in Cell Therapy and Exploring New Paths for Industry Development,” this exchange aimed to foster deep alignment in medical technology innovation, industrial synergy, and policy implementation. Together, both sides sought to explore new pathways for collaborative development between the Guangdong-Hong Kong-Macao Greater Bay Area and the Hainan Free Trade Port in the field of cell therapy, thereby enhancing the global influence of China’s cell therapy sector.

Accompanied by Shi Yuanyuan, Founder of Deep Harbour Cell Valley, the delegation toured the Cell Valley Smart Exhibition Hall, the multi-site linked laboratories, and the GMP industrial production platform. They gained in-depth insights into the latest progress in frontier technologies for cell and gene therapy, breakthroughs in core key technologies, and practices in integrating resources between Shenzhen and Hong Kong. The leaders from the Lecheng Administrative Bureau spoke highly of Deep Harbour Cell Valley’s exploratory achievements in innovative drug R&D, clinical translation, and international cooperation. In-depth discussions were held on synergizing Lecheng’s policy advantages with Cell Valley’s technical strengths, establishing product quality control systems, and defining pathways for outcome translation.

During the symposium, Shi Yuanyuan warmly welcomed the delegation from the Lecheng Administrative Bureau and Lecheng Holding Company, systematically introducing Deep Harbour Cell Valley’s development layout and phased achievements. He noted that as the first enterprise in the Guangdong Free Trade Zone to benefit from national medical openness pilot policies, Deep Harbour Cell Valley has always focused on full-chain innovation in cell therapy, establishing a comprehensive system covering “basic research – technical breakthroughs – clinical translation – industrial production.” As a “testing ground” for policy breakthroughs in China’s cell therapy sector, the Lecheng Pilot Zone has already established a first-mover advantage in policy innovation, international resource aggregation, and industrial translation. Looking ahead, Deep Harbour Cell Valley is committed to leveraging its internationally advanced experience in cell product manufacturing quality control and core key technologies to actively support Lecheng in building a national highland for cell therapy pilot initiatives.

Gao Huimin introduced the implementation results of Lecheng Pilot Zone’s core policies, including “licensed import of drugs and medical devices,” “application of real-world data,” and “new biomedical technologies.” He pointed out that Deep Harbour Cell Valley’s technical accumulation and Lecheng’s policy advantages are highly complementary. He expressed expectations for pragmatic cooperation between both parties in clinical research of cell therapy products, cross-border applications, and upstream-downstream synergy, jointly accelerating the translation of technological outcomes to benefit more patients.

Zhou Lianghui, from the perspective of industrial carriers and capital linkage, introduced the latest progress of Lecheng Development Holding Company in constructing the Boao Cell Therapy Public Service Center. He stated that Lecheng is accelerating the build-out of an integrated service platform covering R&D, production, and quality control to facilitate the efficient landing of healthcare projects. He expressed hope to establish closer cooperation with Deep Harbour Cell Valley in regional synergy, resource sharing, and the landing of innovative projects, jointly creating a benchmark for cross-regional industrial collaboration.

Both parties agreed to take this exchange as an opportunity to further strengthen strategic synergy. By maximizing the combined effect of policy innovation and technical breakthroughs, they will engage in deeper cooperation in frontier technology R&D, clinical application translation, and international resource integration. Together, they aim to drive a leapfrog development in China’s medical technology innovation and industrialization levels.